Established in 2009, Golden Eagle Biotech is a globally recognized leader in the biotechnology and medical device industry. We are dedicated to conquering complex diseases through an integrated portfolio of innovative therapeutic solutions and precision surgical technologies. With a strategic focus on oncology, neurosurgery, and foundational surgical care, our mission is to empower healthcare professionals and improve patient outcomes worldwide. The company's robust growth, underpinned by disciplined financial strategy, has culminated in a valuation approaching USD 2 billion.

· Series A (2011): Secured initial capital to establish our core R&D platforms and manufacturing facility in China.

· Series B (2015): Funded the expansion of our oncology and neurosurgery pipelines, and the scaling of our surgical instrument production.

· Series C (2021): Enabled advanced clinical trials for our neuro-pharmaceutical division and accelerated global market penetration.

Golden Eagle Global has solidified its position as a premier, fully integrated biotechnology powerhouse. With a robust valuation of US$2 billion, the company is defined by its profitable hyper-growth, global commercial dominance in its core therapeutic areas, and a deep, innovative pipeline that ensures long-term market leadership. H1 2025 performance exceeded expectations, with revenue reaching US$218 million and Net Profit of US$48 million, representing a 22% Net Profit Margin. Our scalable business model, underpinned by high-margin consumables and strategic expansion, continues to deliver exceptional value to our shareholders.

Revenue by Segment (H1 2025):

  · High-Margin Consumables: 68% of revenue (~US$148 million). The cornerstone of our recurring revenue model.

  · Capital Equipment (Systems): 15% of revenue. Placed strategically to drive future consumable sales.

  · Pharmaceutical Division (Neuro): 12% of revenue. High-growth segment with blockbuster potential.

  · Service & Data Solutions: 5% of revenue. Emerging high-margin segment from our "Transplant Cloud" initiative.

· Geographic Revenue Mix: North America: 45%, Europe: 35%, Asia-Pacific: 15%, Rest of World: 5%.

The market potential of our mid-to-late-stage pipeline (Phase II/III and pre-market approval) is estimated at over US$5 billion. :Key assets include

  · GE-101: Next-gen AI-driven Liver Perfusion System (CE Mark obtained, FDA submission in Q4 2023).

  · GE-202: Companion Diagnostic for a novel immuno-oncology drug (in collaboration with a Top-10 Pharma).

  · GE-301: Novel therapeutic for Glioblastoma (Orphan Drug Designation granted in US and EU).

Innovation at Golden Eagle is structured across three synergistic pillars:

1. Oncology Division: We specialize in the development of high-precision diagnostic devices and minimally invasive therapeutic systems for targeted cancer treatments. Our pipeline includes advanced tumor ablation technologies and companion diagnostics.

2. Surgical Solutions Division: We engineer a comprehensive range of high-quality foundational and specialized surgical instruments. Our products are designed for reliability, ergonomics, and precision, supporting surgeons in complex procedures, including neurosurgery and oncology.

3. Neuro-pharmaceuticals Division: Our research is focused on pioneering novel drug candidates for treating complex neurological and brain disorders, creating a holistic approach to patient care that bridges devices and therapeutics.

Our world-class R&D team drives this innovation, bolstered by strategic collaborations with leading academic institutions to ensure we remain at the forefront of scientific discovery.

Our state-of-the-art manufacturing complex in China operates under the highest international quality standards, including ISO 13485 and cGMP. This ensures the superior quality and reliability of every product, from surgical tools to pharmaceutical agents. Golden Eagle's products have gained regulatory approval and are trusted in over 30 countries, including the United States, Canada, United Kingdom, France, Switzerland, and Singapore.